Redfield Robert 4

What Happened

• Robert Redfield, Chief Medical Officer of Traws Pharma (TRAW), was granted 84,000 derivative securities (stock options) on 2026-07-09. The Form 4 reports the acquisition at $0.00, reflecting an award of options rather than an open-market purchase or sale. There was no exercise or sale reported in this filing.

Key Details

• Transaction type: Award/Grant of stock options (derivative).
• Transaction date: 2026-07-09; Form 4 filed: 2026-07-14 (filed 5 days after the transaction).
• Quantity: 84,000 options; reported acquisition price: $0.00.
• Vesting: Per footnote, the options vest 100% on the first anniversary of the grant date.
• Shares owned after transaction: Not disclosed in this filing.
• Timeliness: Filing appears late (filed 5 days after the transaction); Form 4s are typically required within 2 business days.

Context

• This is a compensation grant from the company’s 2021 Incentive Compensation Plan (approved and administered by independent directors). An award grant is routine compensation and does not indicate an immediate cash transaction or sale of shares. The options are not reported as exercised here and will only become exercisable once vested per the stated schedule.